Islet Cell Biology and Regenerative Medicine, Joslin Diabetes Center, Department of Medicine, Harvard Medical School, Boston, MA 02215, USA.
Sci Transl Med. 2010 Sep 15;2(49):49ps47. doi: 10.1126/scitranslmed.3001027.
In the design of therapeutics to treat type 2 diabetes, researchers have exploited the observation that oral ingestion of nutrients leads to the secretion of glucose homeostasis-regulating incretin hormones (for example, glucagon-like-peptide-1) from the gut. Here, we discuss two recent papers that suggest that the "other" incretin hormone, gastric inhibitory polypeptide (GIP), also is important in the regulation of glucose homeostasis. These findings warrant further studies to unravel the mechanism of action of GIP in β-cells of the endocrine pancreas and to evaluate the possibility of designing novel therapeutics that target both incretin hormones.
在设计治疗 2 型糖尿病的疗法时，研究人员利用了这样一种观察结果，即口服摄入营养物质会导致肠道分泌调节葡萄糖稳态的肠促胰岛素激素（例如，胰高血糖素样肽-1）。在这里，我们讨论了两篇最近的论文，它们表明“另一种”肠促胰岛素激素，胃抑制多肽（GIP），在葡萄糖稳态调节中也很重要。这些发现需要进一步的研究来阐明 GIP 在胰岛内分泌细胞中的作用机制，并评估设计针对两种肠促胰岛素激素的新型疗法的可能性。
